SanReno, a China JV, Formed with $40 Million and Two Kidney Disease Drugs
December 01, 2021 at 05:48 AM EST
SanReno Therapeutics, a China joint venture, was formed by Chinook Therapeutics (NSDQ: KDNY) and an investor syndicate led by Frazier Healthcare Partners and Pivotal bioVenture Partners China. The syndicate invested $40 million for a 50% stake in the JV, while Chinook contributed two kidney disease precision medicines for the other 50%. Chinook develops novel kidney candidates via its single cell RNA sequencing, human-derived organoids and new translational models. SanReno has exclusive rights to Chinook's atrasentan and BION-1301 in Greater China. More details.... Share this with colleagues: // //